In this retrospective study, 71 patients with resected stage III melanoma who had received adjuvant anti-programmed cell death protein-1 (PD-1) (±ipilimumab) immunotherapy with a subsequent locoregional (lymph node and/or in-transit metastases) recurrence were identified. This evidence concerns the gene PDCD1 and melanoma.